Efficacy of Empagliflozin in Slowing the Progression of Renal Disease in Patients with Type 2 Diabetes: Single-Blind Interventional Study with Placebo Control at Tertiary Care Setting Quetta

Objective: To assess the role of SGLT2 Inhibitor, Empagliflozin, in slowing renal disease progression in type 2diabetics.Study Design: Single-blind interventional study with placebo control.Place and Duration of Study: The study was carried out at the Department of Nephrology, Combined MilitaryHospital (CMH), Quetta, Pakistan from July 2023 to July 2024.Methods: This was an experimental study with placebo controlinvolving 100 type 2 diabetics (N=100), whowere assigned to receive either Empagliflozin (10 mg OD) or a placebo. Estimated glomerular filtration rate(eGFR) by (CKD-EPI Formula), HbA1C levels, and Urine Protein Creatinine Ratio (UPCR) were measured at 0, 3,and 6 months. Improvement in GFR and reduction in proteinuria & HbA1C levels were taken as primaryobjectives. Three mixed-design analyses of variance over time (baseline, 3 months, 6 months) conducted forsignificance.Results: Average age was 57.44 ± 10.48 years. The treatment group had 47 patients, and the placebo group had53 patients. The treatment group showed a lesser reduction in mean eGFR (70.94mL/min to 68.56mL/min)than the placebo group (69.60mL/min to 62.11mL/min). The treatment group showed a greater decrease inHbA1c levels (8.36% to 7.36%) than the placebo (8.30% to 8.01%). Proteinuria was reduced in the treatmentgroup (2.51 g/day to 1.28 g/day) compared to an increase in the placebo group (2.66 g/day to 3.17 g/day). Allfindings were statistically significant (P < 0.05).Conclusion: In type 2 diabetics, addition of empagliflozin to standardized care resulted in a greater reduction inproteinuria, greater reduction in HbA1c levels, and lesser decline in eGFR, signifying the beneficial effects of thedrug on glycemic control and prevention of renal deterioration. How to cite this: Khan Z, Altaf A, Jhanzaib S, Ijaz MU, Fazal, N, Ikhlaq A. Efficacy of Empagliflozin in Slowing the Progression of Renal Disease in Patients with Type 2 Diabetes: Single-Blind Interventional Study with Placebo Control at Tertiary Care Setting Quetta. Life and Science. 2025; 6(4): 522-527. doi: http://doi.org/10.37185/LnS.1.1.870